The authors describe the case of a 60-year-old man with POEMS syndrome associated with vascular lesions. The patient had osteosclerotic myeloma IgA (λ), polyneuropathy, endocrinopathy, and skin changes. Subsequently, he developed gangrene of the lower limbs with no response to heparin therapy. The humoral study showed thrombocythemia, high levels of interleukin-1beta (IL-1beta) and IL-6 and of some coagulative/fibrinolytic and endothelial factors (von Willebrand factor, plasmin-antiplasmin complexes, plasminogen activator, and endothelial adhesion molecule ICAM-1). The authors suggest that these factors, induced by the increased levels of cytokines, could be responsible for microvascular damage, gangrene, and heparin resistance.
Get full access to this article
View all access options for this article.
References
1.
Crow RS: Peripheral neuritis in myelomatosisBr Med J2:802-804, 1956.
2.
Bardwick PA, Zvaifler NJ, Gill GN: Plasmacell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes: The POEMS syndrome. Medicine ( Baltimore) 59:311-322, 1980.
3.
Waldestrom JG : POEMS: A multifactorial syndromeHaematologica77:197-203, 1992.
4.
Tartour E., Adams D., Besancenot JF, et al : POEMS syndrome with high interleukin (IL)6 and ILlbeta serum levels in a patient with thyroid carcinoma and melanoma. Eur J Cancer30A:893-894, 1994.
5.
Nakanischi T. , Sobue I., Toyokura Y.: The Crow-Fukase syndrome: A study of 102 cases in Japan. Neurology34:712-720, 1984.
6.
Mandler RN, Kerrigan DP, Smart J., et al: Castleman's disease in POEMS syndrome with elevated interleukin-6Cancer69:2697-2703, 1992.
7.
Emile C., Danon F., Fermand JP, et al: Castleman's disease in POEMS syndrome with elevated interleukin-6Cancer71:874, 1993.
8.
Andres E.: POEMS syndrome: Role and value of interleukin-6Rev Med Interne17:145-149, 1996.
9.
Morley JB, Schweiger AC: The relation between chronic polyneuropathy and osteosclerotic myelomaJ Neurol Neurosurg Psychiatry30:432-442, 1967.
10.
Zenone T., Bastion Y., Salles G., et al: POEMS syndrome, arterial thrombosis and thrombocythaemiaJ Intern Med240:107-109, 1996.
11.
Gherardi RK : Proinflammatory cytokines: A pathogenic key of POEMS syndrome. Rev Neurol152:409-412, 1994.
12.
Gherardi RK , Bélec L., Fromont G., et al: Elevated levels of interleukin-1beta (IL-1beta) and IL-6 in serum and increased production of IL-1beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndromeBlood83:2587-2593, 1994.
13.
Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factorJ Exp Med163:740-745, 1986.
14.
Bussolino F. , Breviario F., Tett C., et al: Interleukin-1 stimulates platelet activating factor production in cultured human endothelial cellsJ Clin Invest77:2027-2033, 1986.
15.
Bevilacqua MP, Pober JS, Majeau GR, et al: Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cellsJ Exp Med160:618-623, 1984.
16.
Yamada M., Yamawaki M., Michikawa M., et al : The Crow-Fukase (POEMS) syndrome with vasospastic anginaEur Neurol34:110, 1994.
17.
Bar-Shavit R., Eldor A., Vlodavky I.: Binding of thrombin to subendothelial extracellular matrix: Protection and expression of functional propertiesJ Clin Invest84:1096-1104, 1989.
Glimelius B. , Busch C., Hook M.: Binding of heparin on the surface of cultured human endothelial cellsThromb Res12:773-782, 1978.
20.
Hogg PJ, Jackson CM: Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implication for heparin efficacy. Proc Natl Acad Sci USA86:3619-3623, 1989.
21.
Young E., Prins M., Levine MN, et al: Heparin binding to plasma proteins, an important mechanism of heparin resistanceThromb Haemost67:639-643, 1992.
22.
Lane DA, Pejler G., Flynn AM, et al: Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4J Biol Chem261:3980-3986, 1986.
